Free Trial
LON:EKF

EKF Diagnostics (EKF) Share Price, News & Analysis

EKF Diagnostics logo
GBX 25.20 -0.75 (-2.89%)
(As of 11:52 AM ET)

About EKF Diagnostics Stock (LON:EKF)

Key Stats

Today's Range
25.10
26.30
50-Day Range
25
30.90
52-Week Range
23
34
Volume
227,059 shs
Average Volume
391,896 shs
Market Capitalization
£114.34 million
P/E Ratio
2,520.00
Dividend Yield
3.97%
Price Target
N/A
Consensus Rating
N/A

Company Overview

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Receive EKF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EKF Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

EKF Stock News Headlines

Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
EKF Diagnostics Holdings PLC (LYF.BE)
LYF.SG,0P0001KKD5,0 (LYF.SG)
See More Headlines

EKF Stock Analysis - Frequently Asked Questions

EKF Diagnostics' stock was trading at GBX 31.65 at the beginning of the year. Since then, EKF stock has decreased by 20.4% and is now trading at GBX 25.20.
View the best growth stocks for 2024 here
.

Shares of EKF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that EKF Diagnostics investors own include ERBA Diagnostics (ERBA), boohoo group (BOO), Lloyds Banking Group (LLOY), 888 (888), Abcam (ABC), ASOS (ASC) and Babcock International Group (BAB).

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
356
Year Founded
N/A

Profitability

Net Income
£4.78 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£50.95 million
Cash Flow
GBX 2.37 per share
Book Value
GBX 15 per share

Miscellaneous

Free Float
N/A
Market Cap
£114.34 million
Optionable
Not Optionable
Beta
0.57
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (LON:EKF) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners